

AGENDA (Version: 7 October 2019)

An Examination of the Ethical, Legal and Social Implications of the WTO TRIPS Agreement on access to gene and cell-based treatments including CAR T and CRISPR

8 - 10 October 2019

*Brocher Foundation
Route d'Hermance 471
1248 Hermance
Switzerland*

Tuesday, 8 October 2019

19:30 Welcome Reception and Dinner (for 21 participants staying at the Brocher Foundation)

Welcome - *Jamie Love and Ellen 't Hoen*

Wednesday, 9 October 2019

9:00 - 9:10: Welcome and introduction - *Thiru Balasubramaniam*

9:10 - 13:00 Science and Technology - An overview of cell and gene based treatments

Discussion moderated by Marie-Paule Kieny and James Love

Advanced medical therapies using genes, cells and tissue, introduction to the science and technology

- **Chimeric antigen receptor T cells (CAR T)**
- **Gene therapies**
- **Clustered regularly interspaced short palindromic repeats (CRISPR)**
- **Etc. (See figure 1 below)**

This is an introduction to the science of the new cell and gene therapies. We have a lot of expertise in the room. The session will last all morning on Wednesday, and begin with initial comments from five persons, and then an open discussion with lots of questions and answers in a roundtable format.

Initial Comments: Hannes Braberg, Diane Singhroy, Paul Fehlner, Robert Watson, Tim Hubbard.

10:30 Coffee Break

Discussion continues

13:00 - 14:00 Lunch

14:00 - 18:00 Exploring challenges and solutions to pricing, access and manufacturing cell and gene-based treatments

Introduction to the challenges of manufacturing, pricing and access, broken into two topics, beginning with manufacturing, and section session on pricing and access. Each session will begin with initial comments from persons, and then an open discussion with lots of questions and answers in a roundtable format.

Manufacturing

Discussion moderated by Paolo Foggi

Initial Comments: Paul Fehlner, Renato Massimi, Robert Watson, Marie Paul Kiény

Pricing and Access

Discussion moderated by Ellen 't Hoen and Vanessa Lopez

Initial Comments: Gaele Krikorian, Marcel Van Raaij, Valerie Paris, Paolo Foggi, Richard Sullivan, Vincenzo Pavone, Polly Webster, Gregg Alton, Charles Gore, James Love,

16:00 - 16:30 Coffee break

16:30 - 18:00 Discussion continued

18:00 Drinks

19:30 Group Dinner

Thursday, 10 October 2019

9:00 - 12:30 Legal and Regulatory barriers to providing access to cell and gene-based treatments

Discussion of legal and regulatory barriers to providing access. Each session will begin with initial comments from persons, and then an open discussion with lots of questions and answers in a roundtable format.

Legal issues - 9:00 - 10:30

Discussion moderated by Thiru Balasubramaniam

Initial Comments: Esther van Zimmeren, Julian Cockbain, Gregg Alton, James Love,

10:30 - 11:00 Coffee break

Regulatory issues - 11:00 - 12:30

Discussion moderated by Yannis Natsis

Initial Comments: Emer Cooke, Marcel Van Raaij

12:30 - 14:00 Lunch and Group Photo

14:00 - 18:00 Normative Proposals, Research Questions, Next Steps

The afternoon session on Thursday will be shaped by the earlier discussions, to ensure that we address topics that need more discussion, and talk about work going forward.

Discussion co-moderated by Ellen 't Hoen and Mariângela Simão


16:00 - 16:30 Coffee break

Discussion continued

19:30 Dinner

Figure 1. Some Cell therapies

CAR T Success Leads to Massive Investment in Cell Therapy



Source:

Aditi Krishnamurthy, Michelle Teicher, Benjamin Leibowitz, Jim Tornatore, Filippo Petti & John Bishai (Wells Fargo)